Feb 10,2023

Abbott is bullish on FreeStyle Libre growth in 2023

Abbott plans to “go more aggressively” into the continuous glucose monitor (CGM) market with its FreeStyle Libre 3 this year. Chair and CEO Robert Ford said on the company’s most recent earnings call that the company expects growth for the platform this year. FreeStyle Libre 3 received FDA clearance in May 2022. Ford cited full-year growth for the Libre platform of 21% overall. Revenues grew by 42% in the U.S., too. Backorders and supply chain issues hampered growth internationally, he noted, but sales still grew in the mid-teens percentage-wise.

PRODUCT

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 09,2023

Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022. In the fourth quarter of 2022, worldwide revenue grew 17% to $815.2 million, up from $698.2 million in the fourth quarter of 2021. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases. Full year revenue grew 19% versus the prior year to $2.91 billion on a reported basis and 20% on an organic basis.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 08,2023

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth

The global blood glucose meters industry size was valued at USD 15.80 billion in 2022 and will register a robust CAGR of around 7.3% from 2023 to 2030

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 08,2023

Dario Partners to Integrate Dexcom CGM Data

DarioHealth Corp. announced today an agreement with Dexcom to integrate its market-leading CGMs, into Dario's multi-chronic condition platform. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 07,2023

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc today unveiled the company’s second Super Bowl commercial, which announces the US launch of its next-generation Dexcom G7 CGM System. The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist, songwriter, actor and philanthropist, Nick Jonas.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 07,2023

Global Glucose Monitoring Devices Market to Reach $19.2 Billion by 2030

the global market for Glucose Monitoring Devices estimated at US$13.1 Billion in the year 2022, is projected to reach a revised size of US$19.2 Billion by 2030, growing at aCAGR of 4.8% over the period 2022-2030. Self-Monitoring Devices, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$11.3 Billion by the end of the analysis period.

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 24,2023

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update

Nemaura Medical, Inc. today releases its financial results for the quarter ending December 31, 2022 and provides a business update. Net loss for the quarter was approximately $1.7million. Cash and cash equivalents at December 31, 2022 were approximately $7.3 million. “We continue to build momentum with our UK programs, while initiating our foothold in the U.S. The recent purchase order from HealthFleet marks the beginning of our commercialization efforts in the U.S., integrating our proBEAT technology into HealthFleet’s RestoreHealth program to potentially improve diabetes management and weight loss.'' commented Nemaura CEO Dr. Faz Chowdhury.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

Abbott Announces Collaborations, Reinforces its Commitment Towards Access to Holistic Diabetes Care

Abbott, the global healthcare leader, announced new collaborations with key health-tech partners BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, Zyla Health, Healthifyme and Fitterfly to usher a new era of holistic diabetes management care. Gautam Chopra, Co-founder & CEO, BeatO commented, “Leveraging Abbott’s FreeStyle Libre with BeatO’s app ecosystem will give our users precise data, along with actionable insights to effectively manage and control blood glucose levels. We are continuously striving to make diabetes management more effective and convenient for our members and this program is a step in the same direction.”

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 25,2020

One Drop Increases Accuracy of AI-powered Hypoglycemia and Hyperglycemia Predictions and Introduces Alert Capability for People Using CGMs

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented new results for continuous glucose monitor-based glucose predictions at The 13th International Conference on Advanced Technologies & Treatments for Diabetes. One Drop’s patent-pending machine learning model accurately predicts the probabilities that a user’s glucose will rise above 180 mg/dL or fall below 70 mg/dL. At 30 minutes, the predictions are 99.5% accurate, at 1 hour, 98.6% accurate, and at 4 hours, One Drop’s accuracy is 91.9%

CLINICAL STUDY

#cgm

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Apr 13,2020

One Drop Acquires Sano

One Drop, a leader in digital care solutions for people living with diabetes and other chronic conditions, today announced it has acquired all of the assets and intellectual property of Sano Intelligence, Inc., an innovator in health sensing technology. The deal was structured as an asset purchase, and several Sano team members will be joining One Drop. The almost decade of work put into developing the Sano continuous glucose sensing platform will live on in a comprehensive multi-sensorial solution from One Drop.

COLLABORATION MERGERS & ACQUISITION

#product & service

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM